Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8N2I9
UPID:
STK40_HUMAN
Alternative names:
SINK-homologous serine/threonine-protein kinase; Sugen kinase 495
Alternative UPACC:
Q8N2I9; D3DPS8; Q5VTK8; Q5VTK9; Q6ZMN1; Q8N2J8; Q8N3I6; Q96HN6; Q96I44; Q9BSA3; Q9H7H6
Background:
Serine/threonine-protein kinase 40, also known by its alternative names SINK-homologous serine/threonine-protein kinase and Sugen kinase 495, plays a crucial role in cellular signaling pathways. This protein is identified by the unique identifier Q8N2I9 and is recognized for its potential regulatory function in inhibiting NF-kappa-B and p53-mediated gene transcription. These pathways are pivotal in controlling cell survival, proliferation, and apoptosis.
Therapeutic significance:
Understanding the role of Serine/threonine-protein kinase 40 could open doors to potential therapeutic strategies. Its involvement in key regulatory pathways suggests that modulation of its activity could have implications in treating diseases where NF-kappa-B and p53 pathways are dysregulated.